Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs

BackgroundInfluenza virus spreads infection by two main surface glycoproteins, namely hemagglutinin (HA) and neuraminidase (NA). NA cleaves the sialic acid receptors eventually releasing newly formed virus particles which then invade new cells. Inhibition of NA could limit the replication of virus to one round which is insufficient to cause the disease.ResultsAn experimentally reported series of acylguanidine zanamivir derivatives was used to develop GQSAR model targeting NA in different strains of influenza virus, H1N1 and H3N2. A combinatorial library was developed and their inhibitory activities were predicted using the GQSAR model.ConclusionThe top leads were analyzed by docking which revealed the binding modes of these inhibitors in the active site of NA (150-loop). The top compound (AMA) was selected for carrying out molecular dynamics simulations for 15 ns which provided insights into the time dependent dynamics of the designed leads. AMA possessed a docking score of −8.26 Kcal/mol with H1N1 strain and −7.00 Kcal/mol with H3N2 strain. Ligand-bound complexes of both H1N1 and H3N2 were observed to be stable for 11 ns and 7 ns respectively. ADME descriptors were also calculated to study the pharmacokinetic properties of AMA which revealed its drug-like properties.

[1]  Sukriti Goyal,et al.  Novel Fragment‐Based QSAR Modeling and Combinatorial Design of Pyrazole‐Derived CRK3 Inhibitors as Potent Antileishmanials , 2014, Chemical biology & drug design.

[2]  N. Cox,et al.  Prevention and control of influenza , 1999, The Lancet.

[3]  A Flahault,et al.  Influenza vaccine: the challenge of antigenic drift. , 2007, Vaccine.

[4]  Gabriele Neumann,et al.  Emergence and pandemic potential of swine-origin H1N1 influenza virus , 2009, Nature.

[5]  J. Dhanjal,et al.  Mechanistic insights into mode of action of a potent natural antagonist of orexin receptor-1 by means of high throughput screening and molecular dynamics simulations. , 2014, Combinatorial chemistry & high throughput screening.

[6]  J. Dhanjal,et al.  Fragment based group QSAR and molecular dynamics mechanistic studies on arylthioindole derivatives targeting the α-β interfacial site of human tubulin , 2014, BMC Genomics.

[7]  M. Zambon,et al.  Epidemiology and pathogenesis of influenza. , 1999, The Journal of antimicrobial chemotherapy.

[8]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[9]  W. L. Jorgensen,et al.  Prediction of drug solubility from structure. , 2002, Advanced drug delivery reviews.

[10]  Jesús S. Dehesa,et al.  Insight into the informational-structure behavior of the Diels-Alder reaction of cyclopentadiene and maleic anhydride , 2014, Journal of Molecular Modeling.

[11]  J. Skehel,et al.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. , 1987, Annual review of biochemistry.

[12]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[13]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[14]  K. Subbarao,et al.  Influenza , 2017, The Lancet.

[15]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[16]  Julian Tirado-Rives,et al.  Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Malbea A Lapete,et al.  Morbidity and Mortality Weekly Report Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices (acip) Centers for Disease Control and Prevention Epidemiology Program Office Early Release 1 Prevention and Control of Influenza Recommendations of the Advis , 2022 .

[18]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[19]  George Kollias,et al.  A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas. , 2009, European journal of medicinal chemistry.

[20]  M. Banning.  Influenza: incidence, symptoms and treatment. , 2005, British journal of nursing.

[21]  Alexander Golbraikh,et al.  Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection , 2004, Molecular Diversity.

[22]  Sukriti Goyal,et al.  Mechanistic insights into mode of actions of novel oligopeptidase B inhibitors for combating leishmaniasis , 2014, Journal of Molecular Modeling.

[23]  Robert V. Swift,et al.  Mechanism of 150-cavity formation in influenza neuraminidase , 2011, Nature communications.

[24]  Sukriti Goyal,et al.  Development of Dual Inhibitors against Alzheimer's Disease Using Fragment-Based QSAR and Molecular Docking , 2014, BioMed research international.

[25]  Sukriti Goyal,et al.  Computational design of novel flavonoid analogues as potential AChE inhibitors: analysis using group-based QSAR, molecular docking and molecular dynamics simulations , 2015, Structural Chemistry.

[26]  S. Jain,et al.  3D QSAR Analysis on Pyrrolidine Derivatives as DPP IV Inhibitors , 2011 .

[27]  Sukriti Goyal,et al.  Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2. , 2014, Journal of molecular graphics & modelling.

[28]  J. Dhanjal,et al.  Mechanistic insights into mode of action of potent natural antagonists of BACE-1 for checking Alzheimer's plaque pathology. , 2014, Biochemical and biophysical research communications.

[29]  Jinn-Moon Yang,et al.  Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. , 2013, Organic & biomolecular chemistry.

[30]  J. Gong,et al.  Structure and functions of influenza virus neuraminidase. , 2007, Current medicinal chemistry.

[31]  Rajeev K. Singla,et al.  QSAR model for predicting the fungicidal action of 1,2,4-triazole derivatives against Candida albicans , 2010, Journal of enzyme inhibition and medicinal chemistry.

[32]  Salma Jamal,et al.  Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships , 2015, BMC Genomics.

[33]  Sukriti Goyal,et al.  Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus , 2014, BMC Bioinformatics.

[34]  David J. Stevens,et al.  The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design , 2006, Nature.

[35]  E. Holmes,et al.  The evolution of epidemic influenza , 2007, Nature Reviews Genetics.